LIANBIO

July 2022

Disclaimer

The information herein contains statements about future expectations, plans and prospects for LianBio. All statements, other than statements of historical fact, included herein are forward-looking statements. Forward-looking statements are not statements of historical fact nor are they guarantees or assurances of future performance. Forward-looking statements are based on LianBio's expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that may cause actual results to materially and adversely differ from those set forth in or implied by such forward-looking statements, including those risks and uncertainties that are described under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021, as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the Securities and Exchange Commission. LianBio undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing LianBio's views as of any date subsequent to the date hereof.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third party sources and LianBio's own internal estimates and research. While LianBio believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of any information obtained from third party sources. In addition, the third party information included in this presentation may involve a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while LianBio believes its own internal research is reliable, such research has not been verified by any independent source.

Investment Highlights

We are a global biopharmaceutical company dedicated to developing and commercializing paradigm-shifting medicines for patients with unmet medical needs in Greater China and other Asian markets

Bringing a pipeline of innovative therapies into the rapidly growing Greater China market

Established pharmaceutical in-licensing and development platform well positioned to capitalize on positive market trends and momentum

Multiple near-term catalysts across a diverse late, mid and early-stage pipeline
Five clinically validated therapeutic candidates, nine in-licensed assets

Experienced cross-border team with BD, alliance management, clinical development, regulatory and commercial expertise and track record

Key validating and differentiating partnerships with Pfizer and BridgeBio

Strong financial position with cash runway through mid 2024; cash balance of $389.1 million as of March 31, 2022, which includes cash, cash equivalents, marketable securities and restricted cash

China is the Second Largest Pharmaceutical Market Today, with Innovation Agenda Propelling Strong Growth

Substantial unmet medical needs persist in China

- **Aging population > 1.4Bn, with a high disease burden** compared to developed countries[1]
- **"Healthy China 2030" sets clear healthcare industry KPIs** from the government[2]
  - Improve key TA mortality rates, including CV and oncology
- Despite increased R&D activity, still **few China-originated first-in-class and best-in-class drugs approved**

Fostering innovation: continued momentum in policy and industry evolution

Comprehensive policies enacted to foster innovation

- China's five-year plan includes innovation priorities in TAs such as oncology and CV[3]
- Accelerated review and approval timelines of patented pharmaceuticals[4]

Expanding coverage and broadening access for innovative drugs

- Growth in basic medical insurance and commercial health insurance[5]
- NRDL now updated annually

Biotech ecosystem growth

- Improving capital markets and fund flows into Chinese biotech
- Increase in number of CROs, bioparks, biotechs, clinical trial centers

Healthcare infrastructure upgrades

- Upgrades to private and public hospitals and community health centers[6]
- Increasing number of healthcare professionals

1. GBD Global Healthdata Exchange 2019; 2. "Healthy China 2030" released by China State Council in July 2019; 3. "14th Five-Year Plan (2021-2025) and the Long-Range Objectives Through the Year 2035; 4. GBI; review time calculated as time interval between NDA submission date and approval date 5. MoHRSS; NRCMS; CIRC website; China Insurance Yearbook; Xrate 6.53 RMB/USD; 6. "Comprehensive Reform of Public Hospitals Notification of Subsidy Fund Budget" released by Ministry of Finance in Nov 2020

China Biotech Sector at Potential Inflection Point for Significant Growth…

Potential U.S./EU Biotech In-licensing Opportunities for China[1]



Early Innings:

- **< 10% of western innovative biotech medicines tapped for China**, and majority of in-licensed programs are concentrated in oncology
- Western biotechs seeking **strategic access to China as part of global enrollment acceleration** and commercial opportunity

1. CapitalIQ. assumes only one opportunity per company based on 10,794 total US/EU biotech companies as of July 2021. 2.Based on 857 cross-border deals from 2015-2020 per ChinaBio.

…LianBio Positioned to Potentially Lead Next Generation of Chinese Biotechs: Speed, Scale and Sustainable Growth

Differentiated Access to Innovation

- **Relationship with our founder** provides expanded BD opportunities, with unparalleled sourcing, access and clinical/scientific due diligence capabilities

PERCEPTIVE ADVISORS

- BD approach informed by
  - Deep scientific expertise
  - Region-specific development insights
  - Regulatory and commercial insights

Cross-Border Execution Platform

- Management team with deep experience and **proven track records across global and Chinese biopharma** companies
- Robust asset and alliance management with bilingual **U.S.-based team dedicated to alliance management**
- **Maximizing asset value** locally and globally through **bespoke development strategies**
  - Ability to facilitate potentially faster market entry through **bridging studies and accelerated pathways**
  - **Unique in-market indications** and combination strategies for **global-first expansion** studies

Commercial Model Provides Optionality

- **Integrated commercial infrastructure** built around **core therapeutic areas**, products and market segments
- **Optionality** to leverage commercial partnerships for **broad access** to select assets

Pfizer

- Commercialization strategies **beyond hospital channels** provide broadened opportunities

Pipeline of Innovative Medicines – 5 Clinically Validated Therapeutic Candidates



1. The commercialization of each of our product candidates will require regulatory approval in the respective jurisdiction in which we intend to market such product candidate; however, obtaining and maintaining regulatory approval in one jurisdiction does not guarantee we will be successful in obtaining or maintaining regulatory approval of the product candidate in other jurisdictions that are material to the success of LianBio. 2. Mavacamten has received FDA approval in the US, which is not a part of our licensed territory, for the treatment of NYHA class II-III obstructive HCM 3. NBTXR3 has received European market approval (CE mark) in the EU, which is not a part of our licensed territory, for the treatment of locally advanced soft tissue sarcoma. At present, we are not pursuing NBTXR3 in relation to this STS indication. 4. Infigratinib has received FDA approval in the US, which is not a part of our licensed territory, for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement. 5. Ongoing Phase 2a gastric cancer and other FGFR-driven tumor standalone clinical trial in China. Separate investigator sponsored Phase 2 clinical trial of infigratinib in FGFR-driven tumors is ongoing in the United States.

Three Key Pillars for Patient Reach and Sustainable Growth

#1 Establish Commercial Footprint with Lead Assets

*** All clinically validated***

- CAMZYOS™ (mavacamten) capsules — Mavacamten
- TP-03
- NBTXR3
- TRUSELTIQ® (infigratinib) capsules — Infigratinib

#2 Leverage Infrastructure

- BBP-398
- LYR-210
- Sisunatovir
- Omilancor
- NX-13

#3 Expand Pipeline via Additional BD

- Deepen existing TA franchises
- Strategic multi-asset partnerships
- Combination opportunities

Oncology | Cardiovascular | Ophthalmology | Inflammatory Diseases | Respiratory

Current Portfolio Could Bring Innovative Medicines to ~16M Patients in China

Diversified pipeline assets address large patient populations across therapeutic areas, including those that have been historically underserved



Note: Figures represent 2020 estimates for indications potentially addressable by mavacamten, NBTXR3, BBP-398, infigratinib, omilancor, NX-13, LYR-210, and sisunatovir
*TP-03 depiction based on <10% current diagnosis rate assumption

LianBio has Rapidly Established a Platform to Serve as a Partner of Choice and Gateway to China

9 assets in-licensed, 3 clinical trials initiated, 7 INDs approved



Experienced Cross-Border Management Team Supported by a Highly Regarded Board of Directors

Management Team

Yizhe Wang, Ph.D.
Chief Executive Officer; Board Member

Debra Yu, M.D.
President & Chief Strategy Officer

Yi Larson
Chief Financial Officer

Pascal Qian
China General Manager

Michael Humphries
Chief Scientific Advisor

Brianne Jahn
Chief Business Officer

Nathan Chen
VP, Regulatory Affairs, Pharmacovigilance and Project Management

Levvy Lv, D. Eng
VP, Clinical Operations & Translational Development

Board of Directors

Konstantin Poukalov
Managing Director – Strategy, Perceptive Advisors; Executive Chairman, LianBio

Yizhe Wang, Ph.D.
Chief Executive Officer, LianBio

Adam Stone
Chief Investment Officer, Perceptive Advisors

Tassos Gianakakos
Former Chief Executive Officer, MyoKardia

Neil Kumar, Ph.D.
Chief Executive Officer, BridgeBio

Susan Silbermann
Former Global President, Emerging Markets, Pfizer

Wei Wei Chen
Former Vice President, Chief Financial Officer, Starbucks China

Significant Commercial Leadership Experience Across Diverse and Relevant Therapeutic Areas, Including Global and China Launch Execution

Select commercialization experience

Cardiometabolic

- Entresto™ (sacubitril/valsartan) tablets 24/26mg · 49/51mg · 97/103mg
- Plavix® Clopidogrel 75mg / 300mg
- Lipitor® atorvastatin calcium tablets
- Norvasc® Amlodipin
- Fraxiparine®
- Avandia® rosiglitazone maleate
- Betaloc®
- Volibris® ambrisentan
- Pradaxa®

Oncology

- 达伯舒® 信迪利单抗注射液 Sintilimab Injection
- Verzenio® abemaciclib
- AFINITOR® (everolimus) tablets
- Votrient™ 200 mg
- SUTENT® 50 mg SUNITINIB Zytostatikum
- GEMZAR® (gemcitabine)
- Arzerra® (ofatumumab) Injection, for intravenous infusion 20 mg/mL
- ALIMTA® pemetrexed
- 爱优特® 呋喹替尼胶囊

Ophthalmology & Other

- Xalatan® latanoprost ophthalmic solution
- Latanoprost
- Zyprexa® IntraMuscular Olanzapine for Injection
- Cialis® (tadalafil) tablets 2.5 mg, 5 mg, 10 mg, 20 mg
- Cymbalta® duloxetine HCl
- TIENAM®
- Redoxon®
- strattera® atomoxetine HCl
- Viread® 300mg tablets tenofovir disoproxil fumarate
- EPIVIR® (lamivudine) ORAL SOLUTION 10 mg/mL
- VFEND®

Inflammatory Disease

- olumiant® (baricitinib) tablets 2 mg
- taltz® (ixekizumab) injection 80 mg/mL
- Benlysta® (belimumab) Intravenous Use 120 mg/vial Subcutaneous Use 200 mg/mL

Respiratory

- ADVAIR DISKUS®
- Pulmicort®
- SINGULAIR® 10mg Tablets montelukast sodium
- RELVAR ELLIPTA® fluticasone furoate/vilanterol
- ANORO® ELLIPTA® umeclidinium/vilanterol
- Ventolin® (albuterol sulfate)

Pipeline

Mavacamten for the Treatment of HCM and HFpEF

- Mavacamten is a **myosin inhibitor** that targets excessive contractility and impaired relaxation, myocardial energetics and compliance
- In development for the treatment of obstructive hypertrophic cardiomyopathy (**oHCM**), non-obstructive hypertrophic cardiomyopathy (**nHCM**) and heart failure with preserved ejection fraction (**HFpEF**)

China Opportunity

- **1.1M - 2.8M HCM** patients in China (67% oHCM / 33% nHCM)
- **3.7M HFpEF** patients, 10-20% of whom may potentially be addressed by mavacamten

Hypertrophic Cardiomyopathy



- **Obstructive HCM (oHCM)**: Characterized by dynamic LV outflow tract obstruction, in which the enlarged and diseased muscle blocks the flow of blood from the left ventricle to the rest of the body.
- **Non-Obstructive HCM (nHCM):** No significant LV outflow tract obstruction (<30 mm Hg) at rest or with provocation. Driven by diastolic impairment due to the enlarged and stiffened heart muscle.

Clinical Activity Demonstrated in oHCM and nHCM

Clinical Data Summary

oHCM:

- Phase 3 EXPLORER-HCM trial demonstrated patients on treatment experienced statistically significant and clinically meaningful improvements
  - Primary endpoint: Improvement of symptoms and functional capacity (improvement in NYHA class and peak VO2)
  - Well-tolerated; safety results were comparable to placebo; only 2% drop out rate

nHCM:

- Phase 2 MAVERICK-HCM trial demonstrated physiologic benefit with dose dependent reduction in serum levels of NT proBNP, with potentially greater benefit in more severe disease

EXPLORER-HCM

Change from Baseline to Week 30			
	Mavacamten (n=123)	Placebo (n=128)	P-value
Primary Endpoint			
Composite functional, n (%) **EITHER** ≥1.5 ml/kg/min increase in pVO2 with ≥1 NYHA class improvement **OR** ≥3.0 ml/kg/min increase in pVO2 with no worsening of NYHA class	45 (37%)	22 (17%)	**0.0005**
Secondary Endpoints			
Post-exercise LVOT peak gradient, mmHg, mean (SD)	-47 (40)	-10 (30)	**<0.0001**
Peak VO2, mL/kg/min, mean (SD)	1.4 (3.1)	-0.1 (3.0)	**0.0006**
NYHA improved ≥ 1 class, n (%)	80 (65%)	40 (31%)	**<0.0001**
KCCQ-CSS, mean (SD)	13.6 (14.4)	4.2 (13.7)	**<0.0001**
HCMSQ-SoB score, mean (SD)	-2.8 (2.7)	-0.9 (2.4)	**<0.0001**

Source: Olivotto et al, Lancet 2020; Ho et al, J Am Coll Cardiol. 2020

Mavacamten Registration Pathway

Global Stage of Development

- **oHCM:** BMS received approval in the U.S. for the treatment of symptomatic NYHA Class II-III oHCM to improve functional capacity and symptoms
  - BMS presented additional supportive data April 2022:
    - Phase 3 VALOR-HCM study demonstrated mavacamten significantly reduced the need for septal reduction therapy (SRT) in patients with severely symptomatic oHCM who had been appropriate for SRT
    - Phase 3 EXPLORER-LTE study demonstrated sustained improvements in clinically meaningful CV outcomes at weeks 48 and 84
- **nHCM:** MyoKardia completed Phase 2 double-blind, placebo-controlled MAVERICK trial in symptomatic nHCM patients; BMS to initiate Phase 3 nHCM trial in 2022
- **HFpEF:** BMS initiated a Phase 2 trial of mavacamten in HFpEF in Feb 2021

China Development Plan

oHCM: P3 EXPLORER-CN China standalone trial ongoing; PK trial complete

- EXPLORER-CN design mimics EXPLORER-HCM, with some changes to account for **China-specific considerations**
  - Primary endpoint: Valsalva LVOTg
  - Secondary endpoints: resting LVOTg, NYHA and KCCQ
  - EXPLORER-CN initiated January 2022
- PK study complete, favorable tolerability & PK profile demonstrated
- Breakthrough Therapy Designation granted in China February 2022

EXPLORER-HCM

Mean (95% CI) Valsalva LVOT gradient



Number of patients at visit

Mavacamten	123	117	118	118	116	118	120	117
Placebo	128	119	119	125	122	125	124	124

NBTXR3 for the Treatment of Solid Tumors

NBTXR3 is a radioenhancer designed to enhance the efficacy of radiotherapy without resulting in additional side effects on surrounding healthy tissue

Illustrative example of NBTXR3 activity



*Dose enhancement determined by Monte Carlo simulation (CEA Saclay, France). In vitro data. Nanobiotix data.

China Opportunity

- **1.3M patients** receive radiation therapy annually as part of their cancer treatment[1]
- **Up to 925K** patients across potential target indications
  - Locally advanced head and neck cancer: ~25K
  - Non-IO potential solid tumor indications: ~150K
  - IO combination potential solid tumor indications: ~750K

1. Based on 2018 data

Broadly Applicable MOA: Clinical Proof of Concept Demonstrated Across Multiple Tumors and IO Combination

Nanobiotix Key Clinical Data

- **NBTXR3 + RT in soft tissue sarcoma**
  - CE mark approval in EU based on Phase 3 study showing 16.1% CRR w/ NBTXR3 +RT vs. 7.9% CRR w/ RT alone
- **P1 Expansion Study 102: NBTXR3 + RT in locally advanced head and neck cancer (n=41 evaluable patients)**
  - 85.4% ORR
  - 63.4% CRR
  - mOS 18.1 months
  - mPFS 10.6 months
- **P1 Study 1100: NBTXR3 + anti-PD-1+ RT in patients with HNSCC, lung metastases and liver metastases (n=16 evaluable patients)**
  - PD-1 naïve ORR: 80% target lesion
  - PD-1 prior non-responder ORR: 45% target lesion
  - Target lesion disease control rate: 94%

Study 1100: Best Observed Target Lesion Response (Evaluable Population n=16)

Best observed target lesion response as per investigator assessment based on RECIST 1.1



Patient D: pCR based on biopsy sample located in the target lesion
* Patient S: Patient with unconfirmed complete response
** Patient N: Lymph node size is 8mm; complete response as per RECIST 1.1

China Development Strategy

- LB plans to enroll patients in China as part of five potential future global Phase 3 trials, beginning with Nanobiotix's ongoing **Phase 3 NANORAY-312 clinical trial of NBTXR3 in locally advanced HNSCC**
- Additional trials to include IO combination approaches

TP-03 for the Treatment of Demodex Blepharitis (DB) and Meibomian Gland Disease (MGD)

TP-03 (lotilaner ophthalmic solution) is a GABA-Cl channel blocker in development for the treatment of Demodex blepharitis (DB), meibomian gland disease (MGD)

China Opportunity

- **43M DB** patients
- **73M Demodex-driven MGD** patients
  - ~50% of Demodex-driven MGD patients also have DB

Target Indications

Demodex Blepharitis (DB)



- Blepharitis is characterized by eye inflammation, burning, and tearing, and may be accompanied by a specific type of debris called “collarettes”
- A significant proportion of blepharitis cases are caused by eyelash follicle infestation by the Demodex parasite

Collarettes Are Pathognomonic Sign of Demodex Infestation

Collarettes Are Composed of Mite Waste Products and Eggs[1]

- Regurgitated undigested material combined with epithelial cells, keratin, and mite eggs
- Contain digestive enzymes, which cause irritation

Meibomian Gland Disease (MGD)



- Common eye condition where the glands do not secrete enough oil or when the oil they secrete is of poor quality
- If left untreated, MGD can cause or exacerbate dry eye symptoms and eyelid inflammation
- Symptoms include dryness, burning, itching, stickiness/ crustiness, watering, light sensitivity, red eyes, foreign body sensation

All Pre-Specified Primary and Secondary Endpoints were Met in Tarsus's Saturn-1 and Saturn-2 Pivotal Trials

Tarsus completed two successful pivotal trials with consistency across endpoints

	Saturn-1 (Pivotal Phase 2b/3) N=421	Saturn-2 (Pivotal Phase 3) N=412	Combined Pivotal Data N=833
Primary Endpoint: Complete Collarette Cure	**44%** vs. 7% (p<0.0001)	**56%** vs. 13% (p<0.0001)	**50%** vs. 10%
Clinically Meaningful Collarette Cure (Grade 0 or 1)	**81%** vs. 23% (p<0.0001)	**89%** vs. 33% (p<0.0001)	**85%** vs 28%
Mite Eradication	**68%** vs. 18% (p<0.0001)	**52%** vs 14% (p<0.0001)	**60%** vs 16%
Lid Erythema Cure	**19%** vs. 7% (p<0.0001)	**31%** vs. 9% (p<0.0001)	**25%** vs 8%

Approximately 90% of patients experienced a clinically meaningful benefit with respect to collarettes, collarette grade improvement and mites per lash

Source: Tarsus Pharmaceuticals

Development and Regulatory Status

U.S.

- **Tarsus has announced plans to submit NDA for TP-03 in DB to U.S. FDA in 2H 2022**
- Phase 2a MGD trial to be initiated 1H 2022

China

- Conduct DB PK trial (N=12)
- Conduct DB **P3 China standalone trial** (N=150, 1:1 randomization)
  - Co-primary endpoints: collarette cure (0-2 collarettes per eyelid) at day 43, mite eradication at day 43
  - Secondary endpoints: composite cure of collarette and erythema (0-2 collarettes per eyelid and grade 0 erythema) at day 43
- Trials expected to be initiated 2H 2022

Infigratinib for the Treatment of FGFR-Driven Cancers

Infigratinib is an orally administered, ATP-competitive, FGFR1-3 tyrosine kinase inhibitor in development for the treatment of patients with FGFR-driven cancers

- **QED received FDA approval of infigratinib for the treatment of patients with previously-treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) harboring an FGFR2 fusion or rearrangement in May 2021**
- **Approval based on meaningful clinical activity demonstrated in Phase 2 trial in chemotherapy-refractory CCA patients with FGFR2 fusions**
  - BICR cORR of 23.1% (95% CI 15.6 – 32.2) in 2nd and later line patients
  - BICR cORR of 34.0% in true 2nd line patients
  - DOR of 5.0 mos (95% CI 3.7–9.3)
  - Infigratinib administered as third-and later-line treatment resulted in meaningful PFS and ORR benefit in patients with CCA and FGFR2 fusions ~7 mos
  - Current SoC (chemo) = ~3 mos PFS in 2L CCA

Phase 2 trial of infigratinib in chemotherapy-refractory CCA patients with FGFR2 fusions (n=108)	
BICR- assessed objective response rate (ORR), % (95% CI)	23.1 (15.6–32.2)
≤1 previous line of therapy (n=50)	34.0
≥2 previous lines of therapy (n=58)	7.4
BICR-assessed best overall response	
Complete Response, n (%)	1 (1.1)
Partial Response, n (%)	24 (22)
Stable Disease, n (%)	66 (61)
Unconfirmed Complete or Partial Response	12 (11)
Progressive Disease, n (%)	11 (10)
Unknown, n (%)	6 (6)
BICR-assessed confirmed or unconfirmed response, % (95% CI)	34.3 (25.4 – 44.0)
BICR-assessed disease control rate, % (95% CI)	84.3 (76.0 – 90.6)
BICR-assessed median duration of response (IQR), months (95% CI)	5.0 (3.7 – 9.3)
BICR-assessed median PFS, months (95% CI)	7.3 (5.6 – 7.6)
Median OS, months (95% CI)	12.2 (10.7 –14.9)

BICR=blinded independent central review

QED's Development and Regulatory Status in the U.S.

- U.S. FDA approval in 2nd line CCA received May 2021
- Ongoing global Phase 3 PROOF-301 trial in 1st line CCA
- Ongoing global Phase 3 trial in urothelial carcinoma
- In Jan 2020 received Fast Track Designation for 1st line CCA

Infigratinib Registration Pathway and China Opportunity

China Opportunity

- Estimated 72,000 patients diagnosed with CCA annually in China vs. 11,000 diagnosed in U.S.
- Estimated 480,000 patients diagnosed with GC annually in China vs. 26,350 diagnosed in U.S.

China Development Strategy and Regulatory Pathway

- LB will enroll patients in China as part of QED's ongoing global Phase 3 PROOF trial in first-line CCA
- LB initiated a Phase 2a proof of concept trial in China for FGFR2-amplified gastric cancer and other solid tumors with FGFR alterations

Cholangiocarcinoma Annual Incidence



Gastric Cancer Annual Incidence



Additional Pipeline Programs

BBP-398 (SHP2 inhibitor) for the treatment of MAPK pathway-driven solid tumors

- Differentiated profile with a shorter-half life, attractive PK/PD and clean tox
- SHP2 inhibitors have broad potential applications across a variety of tumors and are being developed as combination therapy

LYR-210 (implantable drug matrix) for the treatment of chronic rhinosinusitis (CRS) with 3.4M medically refractory patients in China

- Implantable drug matrix designed to consistently and locally elute mometasone furoate (steroid) to inflamed mucosal sinus tissue for up to six months with a single administration for surgically naïve patients
- Clinically validated with Ph2 statistically significant symptom improvement vs. control at 16, 20 and 24 weeks

Sisunatovir (fusion inhibitor) for the treatment of respiratory syncytial virus (RSV)

- No SAEs observed across ~200 patients treated to date; no cardiac toxicity observed to date, a key issue leading to failure of prior fusion inhibitors
- Potential applicability in high-risk patient segments including pediatric, elderly patients

Omilancor (LANCL2 agonist) for the treatment of IBD

- Oral, gut-restrictive mechanism (lack of systemic exposure) designed for a safe and convenient route of administration for treatment of moderate to severe IBD
- Rapidly growing IBD incident population in China

NX-13 (NLRX1 agonist) for the treatment of IBD

- In Ph1a safety study, NX-13 was shown to be well tolerated

Major Validating Milestones Highlight Strength of LianBio Business Development Engine

Partner	LianBio Partnership Date	Asset Milestone Post-Partnership
MYOKARDIA Mavacamten Bristol Myers Squibb	Aug 2020	✓ **Oct 2020:** MyoKardia **acquired by BMS for $13.1B** ✓ **Apr 2022:** BMS received **U.S. FDA approval** of mavacamten for patients with symptomatic oHCM
REVIRAL Sisunatovir Pfizer	Mar 2021	✓ **Apr 2022:** Reviral enters agreement to be **acquired by Pfizer for up to $525M**
bridgebio QED therapeutics a bridgebio company Infigratinib HELSINN	Oct 2019	✓ **May 2021:** QED received **FDA approval** of infigratinib for patients with previously treated cholangiocarcinoma ✓ **Mar 2021 & 2022:** Helsinn Group and QED enter into and expand **infigratinib strategic collaboration**
tarsus TP-03	Mar 2021	✓ **Jun 2021:** **Positive pivotal results** in Tarsus's SATURN-1 trial (P2b/3 DB) – all primary and secondary endpoints met ✓ **May 2022:** **Positive pivotal results** in Tarsus's SATURN-2 trial (P3 DB) – all primary and secondary endpoints met
bridgebio navire a bridgebio company BBP-398 Bristol Myers Squibb	Oct 2019	✓ **May 2022:** BridgeBio and BMS enter into **BBP-398 strategic collaboration**

Strategic Partnerships Provide Optionality with Differentiated Access to Commercial Infrastructure and Pipeline Opportunities

A differentiated strategic collaboration that provides sourcing, development and commercial optionality

- Provides LianBio and partners optionality to access **Pfizer's established commercial infrastructure** with a highly compliant, secure commercial engine
- At LianBio's election and Pfizer's ROFN, we can jointly develop and commercialize certain LianBio products
- Companies are also working together to **source, select and develop/register leading products for China**
  - Pfizer will contribute up to $70M of non-dilutive capital for in-licensing and co-development activities

Preferential access to an innovative pipeline of more than 20 product development candidates

- BridgeBio is developing transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio is **advancing a broad, innovative pipeline** across rare disease, oncology, dermatology, and other indications
- LianBio already holds China rights to two of BridgeBio's oncology assets, **infigratinib** and **BBP-398**

Targeting 3 Additional Registrational Trial Initiations and Multiple Catalysts by End of 2022

Therapeutic Area	Program	Milestone / Catalyst	Anticipated Timing
Cardiovascular	Mavacamten	▪ Initiate Phase 3 EXPLORER-CN clinical trial in patients with oHCM	✓ Jan 2022
		▪ Mavacamten granted BTD for oHCM in China	✓ Feb 2022
		▪ *U.S. FDA approval for the treatment of symptomatic oHCM (BMS)*	✓ April 2022
		▪ Completion of PK trial in China, demonstrating favorable safety, tolerability and PK profile	✓ May 2022
		▪ Complete enrollment in Phase 3 EXPLORER-CN clinical trial in patients with oHCM	H2 2022
Ophthalmology	TP-03	▪ *Saturn-2 pivotal trial readout (Tarsus)*	✓ Apr 2022
		▪ Initiate Phase 3 clinical trial in patients with Demodex blepharitis in China	H2 2022
Oncology	NBTXR3	▪ *Global trial initiation of Phase 3 NANORAY-312 clinical trial in head and neck cancer (Nanobiotix)*	✓ Jan 2022
		▪ Initiate China portion of Phase 3 NANORAY-312 clinical trial in patients with head and neck cancer	H2 2022
	Infigratinib	▪ Initiate China portion of Phase 3 PROOF-301 clinical trial in patients with first line cholangiocarcinoma	H2 2022

Partner milestones

Investment Highlights

We are a global biopharmaceutical company dedicated to developing and commercializing paradigm-shifting medicines for patients with unmet medical needs in Greater China and other Asian markets

Bringing a pipeline of innovative therapies into the rapidly growing Greater China market

Established pharmaceutical in-licensing and development platform well positioned to capitalize on positive market trends and momentum

Multiple near-term catalysts across a diverse late, mid and early-stage pipeline
Five clinically validated therapeutic candidates, nine in-licensed assets

Experienced cross-border team with BD, alliance management, clinical development, regulatory and commercial expertise and track record

Key validating and differentiating partnerships with Pfizer and BridgeBio

Strong financial position with cash runway through mid 2024; cash balance of $389.1 million as of March 31, 2022, which includes cash, cash equivalents, marketable securities and restricted cash